Patents by Inventor Stephane Perreault

Stephane Perreault has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250163030
    Abstract: Provided herein is a compound of Formula (I) wherein the various substituents are described herein.
    Type: Application
    Filed: October 24, 2024
    Publication date: May 22, 2025
    Inventors: Gayatri Balan, Jayaraman Chandrasekhar, Jonah J. Chang, Kevin S. Currie, Stephen D. Holmbo, Jesse M. Jacobsen, Jeffrey E. Kropf, Seung H. Lee, Yasamin Moazami, Leena B. Patel, Thomas J. Paul, Stephane Perreault, Patrick J. Salvo, Jennifer A. Treiberg, Heath A. Weaver
  • Publication number: 20250100998
    Abstract: Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, together with a pharmaceutically acceptable excipient thereof, and a method of treating cancer with the same.
    Type: Application
    Filed: July 26, 2024
    Publication date: March 27, 2025
    Inventors: Jayaraman Chandrasekhar, Jonah J. Chang, Kevin S. Currie, Stephen D. Holmbo, Jesse M. Jacobsen, David L. Kukla, Seung H. Lee, Yasamin Moazami, Leena B. Patel, Thomas J. Paul, Stephane Perreault, Patrick J. Salvo, Jennifer A. Treiberg, Heath A. Weaver
  • Patent number: 12240862
    Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: March 4, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Daniel H. Byun, Eda Y. Canales, Laurent P. Debien, Petr Jansa, Rick A. Lee, Jennifer A. Loyer-Drew, Stephane Perreault, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Jennifer A. Treiberg, Joshua J. Van Veldhuizen, Lianhong Xu
  • Publication number: 20250066328
    Abstract: Provided herein is a compound of Formula (I): or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present disclosure, together with a pharmaceutically acceptable excipient thereof, and a method of treating cancer with the same.
    Type: Application
    Filed: July 25, 2024
    Publication date: February 27, 2025
    Inventors: Jonah J. Chang, Jayaraman Chandrasekhar, Kevin S. Currie, Stephen D. Holmbo, Jesse M. Jacobsen, David L. Kukla, Seung H. Lee, Yasamin Moazami, Leena B. Patel, Thomas J. Paul, Stephane Perreault, Patrick J. Salvo, Jennifer A. Treiberg, Heath A. Weaver
  • Publication number: 20250032473
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Application
    Filed: June 11, 2024
    Publication date: January 30, 2025
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Patent number: 12053462
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Grant
    Filed: July 19, 2021
    Date of Patent: August 6, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Patent number: 11976083
    Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: May 7, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Eda Y. Canales, Weng K. Chang, Laurent P. Debien, Petr Jansa, Jennifer A. Loyer-Drew, Luisruben P. Martinez, Stephane Perreault, Gary B Phillips, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Jennifer A. Treiberg, Joshua J. Van Veldhuizen
  • Publication number: 20230365529
    Abstract: Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, together with a pharmaceutically acceptable excipient thereof, and a method of treating cancer with the same.
    Type: Application
    Filed: January 26, 2023
    Publication date: November 16, 2023
    Inventors: Jayaraman Chandrasekhar, Jonah J. Chang, Kevin S. Currie, Stephen D. Holmbo, Jesse M. Jacobsen, David L. Kukla, Seung H. Lee, Yasamin Moazami, Leena B. Patel, Thomas J. Paul, Stephane Perreault, Patrick J. Salvo, Jennifer A. Treiberg, Heath A. Weaver
  • Publication number: 20230183216
    Abstract: Provided herein is a compound of Formula (I) wherein the various substituents are described herein.
    Type: Application
    Filed: October 27, 2022
    Publication date: June 15, 2023
    Inventors: Gayatri Balan, Jayaraman Chandrasekhar, Jonah J. Chang, Kevin S. Currie, Stephen D. Holmbo, Jesse M. Jacobsen, Jeffrey E. Kropf, Seung H. Lee, Yasamin Moazami, Leena B. Patel, Thomas J. Paul, Stephane Perreault, Patrick J. Salvo, Jennifer A. Treiberg, Heath A. Weaver
  • Publication number: 20230041518
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Application
    Filed: July 19, 2021
    Publication date: February 9, 2023
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Publication number: 20230002412
    Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
    Type: Application
    Filed: April 28, 2021
    Publication date: January 5, 2023
    Inventors: Eda Y. Canales, Weng K. Chang, Laurent P. Debien, Petr Jansa, Jennifer A. Loyer-Drew, Luisruben P. Martinez, Stephane Perreault, Gary B. Phillips, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Jennifer A. Treiberg, Joshua J. Van Veldhuizen
  • Publication number: 20220227787
    Abstract: The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
    Type: Application
    Filed: December 21, 2021
    Publication date: July 21, 2022
    Inventors: Daniel H. Byun, Eda Y. Canales, Laurent P. Debien, Petr Jansa, Rick A. Lee, Jennifer A. Loyer-Drew, Stephane Perreault, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Jennifer A. Treiberg, Joshua J. Van Veldhuizen, Lianhong Xu
  • Publication number: 20220226337
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Application
    Filed: December 14, 2021
    Publication date: July 21, 2022
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Publication number: 20220152014
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Application
    Filed: October 22, 2021
    Publication date: May 19, 2022
    Applicant: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Publication number: 20220135561
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Application
    Filed: October 13, 2021
    Publication date: May 5, 2022
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Publication number: 20220119383
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Application
    Filed: October 29, 2019
    Publication date: April 21, 2022
    Inventors: Peter A. Blomgren, Taryn L. Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole A. Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer A. Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Patent number: 11224600
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: January 18, 2022
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Patent number: 11179383
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: November 23, 2021
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Patent number: 11174256
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: November 16, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Patent number: 11116760
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: September 14, 2021
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao